Patents by Inventor Harpreet Singh

Harpreet Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS
    Publication number: 20230002464
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: September 2, 2022
    Publication date: January 5, 2023
    Inventors: Colette SONG, Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
  • B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS
    Publication number: 20230002463
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: August 26, 2022
    Publication date: January 5, 2023
    Inventors: Colette SONG, Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
  • Peptides and T cells for use in immunotherapeutic treatment of various cancers
    Patent number: 11541107
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: January 3, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Systems and methods for using hierarchical ordered weighted averaging for providing personalized media content
    Patent number: 11544315
    Abstract: An electronic device, for each media content item of a plurality of media content items, receives a respective score for each of a first set of objectives and a second set of objectives and generates a respective score between a user and the media content item. The generating includes applying a first ordered weighted average to the respective scores for the first set of objectives, to produce a first combined score for the first set of objectives, applying a second ordered weighted average to the respective scores for the second set of objectives, to produce a second combined score for the second set of objectives and applying a third ordered weighted average to the combined score for the first set of objectives and the second set of objectives. The electronic device provides media content to the user based on the respective scores between the user and the media content items.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: January 3, 2023
    Assignee: Spotify AB
    Inventors: Rishabh Mehrotra, Harpreet Singh, Madaline Minuet Kirwin, Edward Lee, Adam Latour Piel
  • Spatially consistent representation of hand motion
    Patent number: 11538282
    Abstract: Examples are disclosed that relate to representing recorded hand motion. One example provides a computing device comprising a logic subsystem and a storage subsystem comprising instructions executable by the logic subsystem to receive a recorded representation of hand motion determined relative to a virtual model aligned to a first instance of an object, receive image data corresponding to an environment, and recognize a second instance of the object in the environment. The instructions are further executable to align the virtual model to the second instance of the object, and output a parametric representation of hand motion for display relative to the virtual model as aligned to the second instance of the object, such that the parametric representation is spatially consistent with the recorded representation of hand motion relative to the virtual model as aligned to the first instance of the object.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: December 27, 2022
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Harpreet Singh Sawhney, Ning Xu
  • Personalized immunotherapy against several neuronal and brain tumors
    Patent number: 11529401
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: December 20, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Sabrina Kuttruff-Coqui, Toni Weinschenk, Jens Fritsche, Steffen Walter, Norbert Hilf, Oliver Schoor, Colette Song, Harpreet Singh
  • Personalized immunotherapy against several neuronal and brain tumors
    Patent number: 11529400
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: December 20, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Sabrina Kuttruff-Coqui, Toni Weinschenk, Jens Fritsche, Steffen Walter, Norbert Hilf, Oliver Schoor, Colette Song, Harpreet Singh
  • Personalized immunotherapy against several neuronal and brain tumors
    Patent number: 11524059
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: December 13, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Sabrina Kuttruff-Coqui, Toni Weinschenk, Jens Fritsche, Steffen Walter, Norbert Hilf, Oliver Schoor, Colette Song, Harpreet Singh
  • NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
    Publication number: 20220389068
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: July 22, 2022
    Publication date: December 8, 2022
    Inventors: Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
  • PEPTIDES AND T CELLS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS
    Publication number: 20220387566
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 25, 2021
    Publication date: December 8, 2022
    Inventors: Andrea MAHR, Toni WEINSCHENK, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Aligning input image data with model input data to generate image annotations
    Patent number: 11514648
    Abstract: An image data annotation system automatically annotates a physical object within individual images frames of an image sequence with relevant object annotations based on a three-dimensional (3D) model of the physical object. Annotating the individual image frames with object annotations includes updating individual image frames within image input data to generate annotated image data that is suitable for reliably training a DNN object detection architecture. Exemplary object annotations that the image data annotation system can automatically apply to individual image frames include, inter alia, object pose, image pose, object masks, 3D bounding boxes composited over the physical object, 2D bounding boxes composited over the physical object, and/or depth map information.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: November 29, 2022
    Assignee: MICROSOFT TECHNOLOGY LICENSING, LLC
    Inventors: Harpreet Singh Sawhney, Ning Xu, Amol Ashok Ambardekar, Moses Obadeji Olafenwa
  • IMMUNOTHERAPY WITH B*07 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS
    Publication number: 20220372104
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 3, 2022
    Publication date: November 24, 2022
    Inventors: Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH, Gisela SCHIMMACK, Michael ROEMER
  • A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS
    Publication number: 20220370583
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: July 29, 2022
    Publication date: November 24, 2022
    Inventors: Colette SONG, Linus BACKERT, Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
  • PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS
    Publication number: 20220362362
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: June 28, 2022
    Publication date: November 17, 2022
    Inventors: Sabrina KUTTRUFF-COQUI, Toni WEINSCHENK, Jens FRITSCHE, Steffen WALTER, Norbert HILF, Oliver SCHOOR, Colette SONG, Harpreet SINGH
  • PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS
    Publication number: 20220362363
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: June 28, 2022
    Publication date: November 17, 2022
    Inventors: Sabrina KUTTRUFF-COQUI, Toni WEINSCHENK, Jens FRITSCHE, Steffen WALTER, Norbert HILF, Oliver SCHOOR, Colette SONG, Harpreet SINGH
  • A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS
    Publication number: 20220362364
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: July 19, 2022
    Publication date: November 17, 2022
    Inventors: Colette SONG, Linus BACKERT, Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
  • PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS
    Publication number: 20220363717
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 3, 2022
    Publication date: November 17, 2022
    Inventors: Andrea MAHR, Toni WEINSCHENK, Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
    Publication number: 20220363729
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: July 8, 2022
    Publication date: November 17, 2022
    Inventors: Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
  • NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
    Publication number: 20220363730
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: July 29, 2022
    Publication date: November 17, 2022
    Inventors: Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
  • Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
    Patent number: 11498948
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: November 15, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Colette Song, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh